Skip to content
Medical Health Aged Care, Research Development

NEW RESEARCH FINDS PLACENTA CELLS MAY LOWER BLOOD PRESSURE

La Trobe University 2 mins read

For immediate release
31 January 2024

Scientists from La Trobe University and the Hudson Institute have demonstrated that cells from placentas could have therapeutic benefits for patients suffering from high blood pressure.

The research, led by La Trobe Senior Lecturer in Physiology and Pharmacology, Dr Michael De Silva, and published in Scientific Reports, has advanced La Trobe’s recent studies into using placenta cells for stroke recovery, has passed human safety trials.

In the next phase, this new therapy will be assessed for its efficacy at reducing disability caused by stroke, pending Therapeutic Goods Administration approval.

“Here we have built on the groundbreaking results of La Trobe’s previous studies using these cells in stroke models,” Dr De Silva said. “If infused within a day after a stroke, the cells target the affected area of the brain, and reduce inflammation and nerve cell death."

“We realised that we could test if similar protection could be seen in reducing the damage high blood pressure causes in the body and we found that the treatment reduced inflammation in blood vessels," Dr De Silva said.

High blood pressure, also known as hypertension, is the leading cause of strokes and heart attacks, and over time creates inflammation in the arteries and can lead to vascular dementia. More than one in every three Australians over the age of 18 has high blood pressure.

The research team at La Trobe led by Dr Michael De Silva, Dr Quynh Nhu Dinh, and Professor Chris Sobey found that the cells, collected by the Hudson Institute from placentas donated by mothers after caesareans, reduced inflammation and prevented cognitive impairment.

"Blood pressure control rates are at an alarmingly low level of 32 per cent in Australia. While a drug can reduce high blood pressure, these cells could target inflammation in the arteries caused by hypertension and therefore reduce the associated risks of cardiovascular disease and cognitive impairment," Dr De Silva said.

Dr De Silva said while the research was in its early stages and the team would continue to work on how this knowledge may benefit patients with high blood pressure, he was satisfied to see that this research could eventually lead to a new form of therapy that reduced damage to blood vessels and the brain when blood pressure was high.

For further interviews, contact Sue Smethurst: [email protected], 0418 643 520

Media

More from this category

  • General News, Medical Health Aged Care
  • 12/03/2026
  • 14:07
Parliament of Australia

Public hearing concerning the National Redress Scheme

TheJoint Standing Committee on Implementation of the National Redress Schemewill hold a public hearing in Canberra on Friday, 13 March 2026, for itsinquiry into the continuing operation of the Scheme. Committee Chair, Ms Jodie Belyea MP, said the Committee is grateful for the contributions made in support of the inquiry to date. ‘The National Redress Scheme plays a central role in Australia’s response to institutional child sexual abuse. It is an important program for a significant number of people. The Committee has received a substantial number of submissions in support of our current inquiry, and public hearings over the coming…

  • Energy, Medical Health Aged Care
  • 12/03/2026
  • 12:11
Sweltering Cities

The cost of keeping cool is making Australians sick: New report reveals millions forced to ration cooling during record heat

12 March 2026 Sweltering Cities has today released the findings of its 2026 Summer Survey, exposing a national health crisis driven by the rising cost of keeping cool. With data from more than 2,600 respondents across 766 postcodes, the report proves that for many Australians the high cost of staying cool is having serious physical and mental health impacts. The 2025/26 summer saw 68% of all respondents report feeling unwell due to heat. However, the survey reveals that this burden is falling most heavily on those already struggling with the cost of living. For renters and people with disabilities, the…

  • Medical Health Aged Care
  • 12/03/2026
  • 10:01
Monash University

Monash Researchers Awarded up to $22.4 Million AUD to Develop New Medicines for Restoring Lymphatic Pumping

Monash University is partnering with the University of Missouri and the University of Pennsylvania to develop first-in-class medicines designed to reverse poor lymphatic vessel contraction and transport function, backed by an up to $22.4 million AUD Award from the Advanced Research Projects Agency for Health (ARPA-H). The researchers join ARPA-H’s GLIDE (Groundbreaking Lymphatic Interventions and Drug Exploration) program to transform how both primary lymphatic diseases and common chronic diseases are treated by developing innovative therapeutics that alleviate, repair or regenerate a dysfunctional lymphatic vascular system. Professor Arthur Christopoulos, Dean of the Faculty of Pharmacy and Pharmaceutical Sciences, said the work…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.